Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Large ribosomal subunit protein uL23 (commonly called L23 in bacteria) is an essential and highly conserved structural protein component of the bacterial 50S ribosomal subunit[5][8]. It participates early in ribosome assembly, binding 23S rRNA, and is crucial for bacterial cell growth[8]. L23 forms part of the polypeptide exit tunnel, where newly synthesized proteins exit the ribosome, and serves as an interaction platform for protein biogenesis factors, such as the chaperone trigger factor and the signal recognition particle[1][2][8]. It is a critical structural and functional element of the translation machinery, making it a target for some antibiotics that bind near or at the tunnel exit to inhibit protein synthesis[1][2]. The protein's functional equivalents in other organisms include L25 in yeast and L23a in eukaryotes[1][5].
Inhibition of protein synthesis by binding near the ribosomal exit tunnel, preventing elongation or proper folding of nascent polypeptides
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Large ribosomal subunit protein uL23 (uL23).